Long acting GLP-1 receptor agonist (injectable)
Bofanglutide 24 mg injection once weekly
BOFANG_SC_24MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -13.78 (-20.74 to -4.67) | 0.84 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -14.80 (-20.16 to -6.51) | 0.92 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.21 (-7.36 to 7.48) | 0.32 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.97 (0.23 to 15.97) | 0.37 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.02 (1.73 to 10.07) | 0.44 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.08 (2.24 to 12.03) | 0.43 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.14 (1.37 to 7.13) | 0.28 |